Physician profile
Nasim Shajihan
NPI 1043211196
$917.36
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $521 · 2020: $137 · 2021: $171 · 2022: $88.07.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $204.11 | 2019-2021 | |
| Otsuka America Pharmaceutical, INC. | $143.80 | 2019-2022 | |
| Ironshore Pharmaceuticals INC. | $136.72 | 2019-2020 | |
| Supernus Pharmaceuticals, INC. | $115.24 | 2021 | |
| Neos Therapeutics, Lp | $80.41 | 2019 | |
| Tris Pharma INC | $53.73 | 2019-2020 | |
| Lundbeck LLC | $44.23 | 2019 | |
| Vertical Pharmaceuticals, LLC | $42.17 | 2019 | |
| Alkermes, INC. | $24.55 | 2019 | |
| Sunovion Pharmaceuticals INC. | $22.37 | 2019 | |
| Pfizer INC. | $21.04 | 2019 | |
| Adlon Therapeutics L.P. | $15.97 | 2019 | |
| Avanir Pharmaceuticals, INC. | $13.02 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nasim Shajihan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.